Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) EBIT Margin (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed EBIT Margin for 3 consecutive years, with 135653.33% as the latest value for Q4 2024.

  • On a quarterly basis, EBIT Margin fell 13481328.0% to 135653.33% in Q4 2024 year-over-year; TTM through Sep 2025 was 477380.0%, a 47544861.0% decrease, with the full-year FY2024 number at 3873.37%, down 367027.0% from a year prior.
  • EBIT Margin was 135653.33% for Q4 2024 at Werewolf Therapeutics, down from 1658.79% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 75.08% in Q2 2023 to a low of 135653.33% in Q4 2024.
  • A 3-year average of 14176.51% and a median of 317.38% in 2022 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: surged 28587bps in 2023, then crashed -13481328bps in 2024.
  • Werewolf Therapeutics' EBIT Margin stood at 180.96% in 2022, then tumbled by -364bps to 840.05% in 2023, then tumbled by -16048bps to 135653.33% in 2024.
  • Per Business Quant, the three most recent readings for HOWL's EBIT Margin are 135653.33% (Q4 2024), 1658.79% (Q2 2024), and 2312.94% (Q1 2024).